Press Briefing
Press Briefing WEBCAST
Presentation Title: GS1-01 Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer
Joyce A. O'Shaughnessy, Stephen Johnston, Nadia Harbeck, et al.
Conclusions At the primary outcome analysis, with a median follow-up of approximately 19 months, abemaciclib combined with ET continued to demonstrate a clinically meaningful improvement in IDFS in patients with HR+, HER2-, node-positive, high risk, EBC with a statistically significant improvement in IDFS in patients with central Ki-67 ≥20%. ClinicalTrials.gov: NCT03155997
------------------------------------------------------------------------------------------------------------------------------------------------------
Presentation Title: GS3-00 First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPONDER)
Kalinsky K, Barlow WE, Meric-Bernstam F, et al.
Conclusions: There is a significant differential treatment effect of CT benefit based on RS for premenopausal vs. postmenopausal women requiring separate analyses. While only 54% of the protocol specified events are recorded and pts will be followed for 15 years, the current data show that adjuvant therapy can be de-escalated to ET alone in postmenopausal pts with a RS < 25 and 1-3 +LN. However, there is a strong IDFS benefit for CET in premenopausal pts, with an early indication of an OS improvement.
------------------------------------------------------------------------------------------------------------------------------------------------------
Under-recognition of Symptoms May Be Common in Patients With Breast Cancer Receiving Radiotherapy
Presentation Title: GS3-07
Identifying patients whose symptoms are under-recognized during breast radiotherapy: Comparison of patient and physician reports of toxicity in a multicenter cohort
Reshma Jagsi, Kent A. Griffith, Frank Vicini, et al.
CONCLUSIONS: PRO collection appears essential for trials because relying on the CTCAE to detect adverse events may miss important symptoms. Moreover, since MDs systematically miss substantial symptoms in certain patients, including pts who are younger or of black or other race, improving symptom detection may be a targetable mechanism to reduce disparities in RT experiences and outcomes.
------------------------------------------------------------------------------------------------------------------------------------------------------
Presentation Title: GS3-08
Persistent controlled substance use following mastectomy with reconstruction surgery
Jacob C Cogan, Rohit R Raghunathan, Melissa P Beauchemin, et al.
Conclusion Among women who underwent M+R, those with a diagnosis of breast cancer, those who received chemotherapy and those who were younger had a higher risk of new chronic controlled substance use. Particular attention should be paid to patients with mental health diagnoses and substance use diagnoses when managing pain, anxiety and sleep disorders.
------------------------------------------------------------------------------------------------------------------------------------------------------
Circulating Tumor Cell Dynamics May Predict Treatment Response and Prognosis in Patients with Metastatic Breast Cancer
Presentation Title: GS4-08
Clinical utility of repeated circulating tumor cell (CTC) enumeration as early treatment monitoring tool in metastatic breast cancer (MBC) - a global pooled analysis with individual patient data
Wolfgang J Janni, Tracy C. Yab, Daniel F. Hayes, et al.
Conclusion: This large pooled analysis confirms that at a median of 35 days after treatment initiation, follow-up CTC assessments strongly predict overall survival. These results suggest potential clinical utility of CTC monitoring as early response marker in MBC, especially in luminal-like tumors.
------------------------------------------------------------------------------------------------------------------------------------------------------
Presentation Title: GS2-03
Prime 2 randomised trial (postoperative radiotherapy in minimum-risk elderly): Wide local excision and adjuvant hormonal therapy +/- whole breast irradiation in women =/> 65 years with early invasive breast cancer: 10 year results
Ian H Kunkler, Linda J Williams, Wilma Jack, et al.
Conclusions: 10 year follow data from the PRIME 2 trial shows that the omission of RT after BCS in women aged ≥ 65 years with T1-2, pN0 hormone receptor positive breast cancer results in only 9.8% IBTR. While this rate is significantly reduced by RT (to 0.9%), the absolute reduction is modest, and there were no differences in the secondary endpoints of distant metastases, contralateral breast cancer or Omitting Radiation Therapy After Breast-Conserving Surgery May Not Impact 10-year Survival Rates for Older Patients With HR-positive Breast Cancer
------------------------------------------------------------------------------------------------------------------------------------------------------
Presentation Title: GS3-09
Chances of pregnancy after breast cancer, reproductive and disease outcomes: A systematic review and meta-analysis
Eva Blondeaux, Marta Perachino, Marco Bruzzone, et al.
Conclusions: This large meta-analysis provides solid evidence on the safety of pregnancy after prior BC diagnosis. The increased risk of fetal and obstetrical complications (but not of congenital abnormalities) calls for ensuring a closer monitoring of these pregnancies. The significantly reduced chances of conceiving as compared to the general population and other cancer patients should raise further awareness on the need to improve the oncofertility counseling of young BC patients wishing to complete their family planning following anticancer treatment completion.